Oncotarget

Meta-Analysis:

Benzodiazepine drug use and cancer risk: a dose–response meta analysis of prospective cohort studies

Tao Zhang _, Xiaowen Yang, Jianrui Zhou, Pei Liu, Hui Wang, Anrong Li and Yi Zhou

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:102381-102391. https://doi.org/10.18632/oncotarget.22057

Metrics: PDF 689 views  |   HTML 1512 views  |   ?  


Abstract

Tao Zhang1,*, Xiaowen Yang2,*, Jianrui Zhou3, Pei Liu4, Hui Wang1, Anrong Li1 and Yi Zhou1

1Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China

2Department of Clinical Laboratory, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China

3Department of Rehabilitation Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China

4Department of Dermatology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China

*These authors contributed equally to this work and are co-first authors

Correspondence to:

Tao Zhang, email: zhang__ta0@sina.com

Keywords: cancer, benzodiazepine, dose-response relationship, meta analysis

Received: July 19, 2017     Accepted: September 21, 2017     Published: October 19, 2017

ABSTRACT

Conflicting results identifying the relationship between benzodiazepine drug use and cancer risk. Therefore, we conducted a dose-response meta-analysis of prospective cohort studies to clarify and quantitative assessed the relationship between benzodiazepine drug use and cancer risk. Up to July 2017, 22 original publications were included in current meta-analysis. Our results showed statistically significant association between benzodiazepine drug use and cancer risk (RR:1.25; 95% CI, 1.15–1.36). Subgroup analysis showed benzodiazepine using was associated with significantly a higher risk of breast cancer (RR:1.15; 95% CI, 1.05–1.26), ovarian cancer (RR:1.17; 95% CI, 1.09–1.25), colon cancer (RR:1.07; 95% CI, 1.02–1.13), renal cancer (RR:1.31; 95% CI, 1.15–1.49), malignant melanoma (RR:1.10; 95% CI, 1.03–1.17), brain cancer (RR:2.06; 95% CI, 1.76–2.43), esophagus cancer (RR:1.55; 95% CI, 1.30–1.85), prostate cancer (RR:1.26; 95% CI, 1.16–1.37), liver cancer (RR:1.22; 95% CI, 1.13–1.31), stomach cancer (RR:1.17; 95% CI, 1.03–1.32), pancreatic cancer (RR:1.39; 95% CI, 1.17–1.64) and lung cancer (RR:1.20; 95% CI, 1.12–1.28). Furthermore, a significant dose-response relationship was observed between benzodiazepine drug use and cancer risk (likelihood ratio test, P < 0.001). Our results showed per 500 mg/year, per 5 year of time since first using, per 3 prescriptions and per 3 year of duration incremental increase in benzodiazepine drug use was associated with a 17%, 4%, 16% and 5% in cancer risk increment. Considering these promising results, increasing benzodiazepine using might be harmful for health.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22057